About this document

Faropenem Efficacy vs. Resistant E. coli & K. pneumoniae by Syeda Umme Sadia is a document available to read on EtoBox.

This study evaluates the in vitro activity and clinical efficacy of Faropenem (FRPM) against third-generation cephalosporin-resistant Escherichia coli and Klebsiella pneumoniae, highlighting its effectiveness in treating urinary tract infections (UTIs). Among 63 patients treated with FRPM, 16% experienced a 28-day relapse, and 25% had a 90-day relapse, with no significant risk factors identified. The findings suggest that FRPM can be utilized based on disk diffusion susceptibility testing, although further

Author

Syeda Umme Sadia

Language

EN